Juvenile-Onset Recurrent Respiratory Papillomatosis in the United States, Epidemiology and HPV Types-2015-2020.
child
human papillomavirus 11
human papillomavirus 6
laryngeal neoplasms
recurrent respiratory papillomatosis
Journal
Journal of the Pediatric Infectious Diseases Society
ISSN: 2048-7207
Titre abrégé: J Pediatric Infect Dis Soc
Pays: England
ID NLM: 101586049
Informations de publication
Date de publication:
17 Aug 2021
17 Aug 2021
Historique:
received:
08
01
2021
accepted:
02
03
2021
pubmed:
20
6
2021
medline:
18
9
2021
entrez:
19
6
2021
Statut:
ppublish
Résumé
Juvenile-onset recurrent respiratory papillomatosis (JORRP) is a rare disease characterized by the growth of papillomas in the respiratory tract. In the United States, JORRP is not a nationally notifiable condition and current data are limited. Children with JORRP aged <18 years were enrolled from 26 pediatric otolaryngology centers in 23 US states from January 2015 through August 2020. Demographic, birth information, and maternal vaccination history were collected from a parent/guardian. Clinical history was abstracted from medical records. Papilloma biopsies were tested for 28 human papillomavirus (HPV) types. Mothers who delivered in 2006 or later were considered age-eligible for HPV vaccination if aged ≤26 years in 2006. We described characteristics of enrolled children and their birth mothers and analyzed disease severity by diagnosis age and HPV type using multiple logistic regression. Among 215 children with JORRP, 88.8% were delivered vaginally; 64.2% were firstborn. Among 190 mothers, the median delivery age was 22 years. Among 114 (60.0%) age-eligible for HPV vaccination, 16 (14.0%) were vaccinated, 1 (0.9%) before delivery. Among 162 specimens tested, 157 (96.9%) had detectable HPV; all 157 had a vaccine-preventable type. Disease severity was associated with younger diagnosis age and HPV 11; adjusted analyses found only younger diagnosis age significant (adjusted odds ratio: 6.1; 95% confidence interval: 2.9, 12.8). Children with JORRP were commonly firstborn and delivered vaginally to young mothers; most of the mothers reported no HPV vaccination before delivery. Vaccine-preventable HPV was identified in all specimens with detectable HPV. Increasing preexposure HPV vaccination could substantially reduce or eliminate JORRP in the United States.
Sections du résumé
BACKGROUND
BACKGROUND
Juvenile-onset recurrent respiratory papillomatosis (JORRP) is a rare disease characterized by the growth of papillomas in the respiratory tract. In the United States, JORRP is not a nationally notifiable condition and current data are limited.
METHODS
METHODS
Children with JORRP aged <18 years were enrolled from 26 pediatric otolaryngology centers in 23 US states from January 2015 through August 2020. Demographic, birth information, and maternal vaccination history were collected from a parent/guardian. Clinical history was abstracted from medical records. Papilloma biopsies were tested for 28 human papillomavirus (HPV) types. Mothers who delivered in 2006 or later were considered age-eligible for HPV vaccination if aged ≤26 years in 2006. We described characteristics of enrolled children and their birth mothers and analyzed disease severity by diagnosis age and HPV type using multiple logistic regression.
RESULTS
RESULTS
Among 215 children with JORRP, 88.8% were delivered vaginally; 64.2% were firstborn. Among 190 mothers, the median delivery age was 22 years. Among 114 (60.0%) age-eligible for HPV vaccination, 16 (14.0%) were vaccinated, 1 (0.9%) before delivery. Among 162 specimens tested, 157 (96.9%) had detectable HPV; all 157 had a vaccine-preventable type. Disease severity was associated with younger diagnosis age and HPV 11; adjusted analyses found only younger diagnosis age significant (adjusted odds ratio: 6.1; 95% confidence interval: 2.9, 12.8).
CONCLUSIONS
CONCLUSIONS
Children with JORRP were commonly firstborn and delivered vaginally to young mothers; most of the mothers reported no HPV vaccination before delivery. Vaccine-preventable HPV was identified in all specimens with detectable HPV. Increasing preexposure HPV vaccination could substantially reduce or eliminate JORRP in the United States.
Identifiants
pubmed: 34145881
pii: 6306271
doi: 10.1093/jpids/piab016
pmc: PMC8446313
mid: NIHMS1719783
doi:
Substances chimiques
Papillomavirus Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
774-781Subventions
Organisme : Intramural CDC HHS
ID : CC999999
Pays : United States
Organisme : CDC HHS
Pays : United States
Informations de copyright
Published by Oxford University Press on behalf of The Journal of the Pediatric Infectious Diseases Society 2021.
Références
Int J Pediatr Otorhinolaryngol. 1993 Mar;26(2):141-7
pubmed: 8383099
Laryngoscope. 2004 Nov;114(11 Pt 2 Suppl 104):1-23
pubmed: 15514560
Clin Infect Dis. 2021 Sep 7;73(5):885-890
pubmed: 33621333
MMWR Morb Mortal Wkly Rep. 2020 Aug 21;69(33):1109-1116
pubmed: 32817598
Pediatr Infect Dis J. 1998 May;17(5):372-6
pubmed: 9613648
Clin Infect Dis. 2000 Jul;31(1):107-9
pubmed: 10913405
Arch Otolaryngol Head Neck Surg. 2004 Jun;130(6):711-6
pubmed: 15210551
Arch Otolaryngol Head Neck Surg. 2006 Jul;132(7):711-5
pubmed: 16847177
Pediatr Dev Pathol. 2001 Jan-Feb;4(1):68-72
pubmed: 11200493
Arch Otolaryngol Head Neck Surg. 2003 Sep;129(9):976-82
pubmed: 12975271
Int J Pediatr Otorhinolaryngol. 2006 Mar;70(3):469-73
pubmed: 16137771
PLoS One. 2014 Nov 24;9(11):e113584
pubmed: 25419846
J Infect Dis. 2018 Jan 4;217(2):208-212
pubmed: 29136168
Otolaryngol Clin North Am. 2019 Aug;52(4):669-679
pubmed: 31078306
Hum Vaccin Immunother. 2019;15(7-8):1942-1948
pubmed: 31107640
Arch Otolaryngol Head Neck Surg. 1999 Jul;125(7):743-8
pubmed: 10406310
Laryngoscope Investig Otolaryngol. 2018 Jan 14;3(1):22-34
pubmed: 29492465
NCHS Data Brief. 2019 Jul;(346):1-8
pubmed: 31442195
Laryngoscope. 1992 Jan;102(1):9-13
pubmed: 1309932
MMWR Recomm Rep. 2014 Aug 29;63(RR-05):1-30
pubmed: 25167164
Acta Otolaryngol. 2020 Sep;140(9):779-784
pubmed: 32491958
Int J Pediatr Otorhinolaryngol. 2020 Jan;128:109697
pubmed: 31698245
J Clin Microbiol. 1997 Dec;35(12):3098-103
pubmed: 9399501
PLoS One. 2019 Jun 13;14(6):e0216697
pubmed: 31194767
Laryngoscope. 1997 Jul;107(7):915-8
pubmed: 9217130
J Infect Dis. 2019 Mar 15;219(7):1016-1025
pubmed: 30358875
Obstet Gynecol. 2013 Nov;122(5):1139-1140
pubmed: 24150030
J Infect Dis. 2009 Mar 15;199(6):805-14
pubmed: 19199546
Laryngoscope. 2005 Oct;115(10):1848-54
pubmed: 16222208
BMC Cancer. 2020 Jun 9;20(1):539
pubmed: 32517663
MMWR Morb Mortal Wkly Rep. 2019 Aug 16;68(32):698-702
pubmed: 31415491
Laryngoscope. 2010 Jun;120(6):1233-45
pubmed: 20513045
Lancet. 2019 Aug 10;394(10197):497-509
pubmed: 31255301
Vaccine. 2006 Aug 31;24 Suppl 3:S3/35-41
pubmed: 16950016
Laryngoscope. 1994 May;104(5 Pt 1):523-7
pubmed: 8189980
Vaccine. 2012 Nov 20;30 Suppl 5:F123-38
pubmed: 23199956